All In Biotech

Drug Trial Radar · NCT02559310

Study to Compare Lefamulin to Moxifloxacin (With or Without Linezolid) for the Treatment of Adults With Pneumonia

A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Lefamulin (BC 3781) Versus Moxifloxacin (With or Without Adjunctive Linezolid) in Adults With Community-Acquired Bacterial Pneumonia

Last checked: Nov 19, 2026Latest source record: Oct 23, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 551 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

551

Actual

Start

Sep 2015

Primary completion

Apr 2017

Study completion May 2017

Sponsor

Lead sponsor
Nabriva Therapeutics AGIndustry
Sponsor type
Industry
First posted
Sep 24, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of lefamulin, a pleuromutilin, for the treatment of adults with moderate to severe community-acquired bacterial pneumonia.

Conditions

  • Community Acquired Pneumonia

Interventions

  • lefamulinDrug

    antibacterial agent

  • MoxifloxacinDrug

    antibacterial agent

  • LinezolidDrug

    antibacterial agent

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Early Clinical Response (ECR)Time frame: ECR was assessed 96 +/- 24 hours after the first dose of study drug.

Locations

99 sites in 18 countries. Site status is shown where the registry gives one.

  • Site 1006

    Hazard, Kentucky

  • Site 1008

    Shreveport, Louisiana

  • Site 1005

    Minneapolis, Minnesota

  • Site 1001

    Butte, Montana

  • Site 1009

    Akron, Ohio

  • Site 1002

    Dayton, Ohio

  • Site 1004

    Splendora, Texas

  • Site 3003

    Córdoba, Argentina

  • Site 3007

    Córdoba, Argentina

  • Site 3001

    Córdoba, Argentina

  • Site 3004

    Córdoba, Argentina

  • Site 3005

    La Plata, Buenos Aires, Argentina

  • Site 3006

    Rosario, Santa Fe Province, Argentina

  • Site 4003

    Mostar, Bosnia and Herzegovina

  • Site 4001

    Tuzla, Bosnia and Herzegovina

  • Site 4004

    Zenica, Bosnia and Herzegovina

  • Site 3104

    Belo Horizonte, Minas Gerais, Brazil

  • Site 3102

    Passo Fundo, Rio Grande Do Sol, Brazil

  • Site 3103

    Campinas, São Paulo, Brazil

  • Site 3101

    Sao Paulo Do Rio Preto, São Paulo, Brazil

  • Site 4105

    Gabrovo, Bulgaria

  • Site 4107

    Lovech, Bulgaria

  • Site 4112

    Pernik, Bulgaria

  • Site 4103

    Rousse, Bulgaria

  • Site 4108

    Smolyan, Bulgaria

  • Site 4102

    Sofia, Bulgaria

  • Site 4101

    Sofia, Bulgaria

  • Site 4106

    Sofia, Bulgaria

  • Site 4110

    Sofia, Bulgaria

  • Site 4111

    Sofia, Bulgaria

  • Site 4104

    Veliko Tarnovo, Bulgaria

  • Site 4109

    Vidin, Bulgaria

  • Site 4206

    Tbilisi, Georgia

  • Site 4204

    Tbilisi, Georgia

  • Site 4205

    Tbilisi, Georgia

  • Site 4201

    Tbilisi, Georgia

  • Site 4202

    Tbilisi, Georgia

  • Site 4305

    Budapest, Hungary

  • Site 4306

    Csorna, Hungary

  • Site 4304

    Debrecen, Hungary

Showing 40 of 99 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.